Puro Pharmaceutical: Subsidiary receives registration certificate for 0.5g Sodium Valproate Sustained-Release Tablets.

Puro Pharmaceuticals announced that its holding subsidiary Zhejiang Puro Kangyu Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate for Sodium Valproate Sustained-Release Tablets issued by the National Medical Products Administration, with a specification of 0.5g. The product has been approved for market authorization as a Class 4 chemical drug, equivalent to passing the generic drug consistency evaluation, and is mainly used for the treatment of generalized seizures, partial seizures, and manic episodes associated with bipolar disorder. According to relevant data, the domestic market size of this drug in 2025 is estimated to be around 580 million tablets, with sales amounting to approximately 1.05 billion yuan. This approval will further enrich the company's product line.